CAS Chemical Supplier Insights℠

CAS Chemical Supplier Insights lets you promote your chemical catalogs in CAS market-leading research solutions to reach chemists, biologists, and formulators.

Contact us
Hexagon shaped overlay
  • Increase sales

    Reach thousands of potential buyers when they are making purchasing decisions.

    Download brochureIncrease sales
    View blog post
  • Gain insights

    See detailed reports on your catalog performance and the substance market space.

    Preview reportsGain insights
    View blog post
  • Increase visibility

    Be seen by users of CAS SciFinder®: the world’s most popular chemical information solution.

    Explore SciFinderIncrease visibility
    View blog post
  • Expand your reach to users of CAS Solutions

    440 thousand+ active CAS SciFinder users

    70+ million annual searches

    3.7+ million supplier results displayed

    Get started

    A ribbon icon

    Existing customers

    To edit or update your catalog data, please see the Supplier Data Submissions instructions.
    A computer icon with data visualization on the screen.

    Join the program

    If you are interested in joining the CAS Chemical Supplier Insights program, click here to learn more about the program.

    Latest from CAS Insights™

    Drug Discovery

    Emerging drug discovery trends explored in CAS Insights webinar

    From microbiome breakthroughs to AI-powered simulations, this CAS Insights webinar recap explores the latest drug discovery trends shaping pharmaceutical research.
    |Webinar
    Emerging Science

    Nobel Prize winners

    Discover how Nobel-winning science unfolds—from breakthrough ideas to global recognition. CAS Insights reveals the context, challenges, and impact behind these discoveries.
    |Article
    Drug Discovery

    Theranostics: How nuclear medicine is changing precision oncology

    Nuclear medicine's theranostics approach enables "see it, treat it" cancer therapy using the same agents for diagnosis and treatment. Investment tripled to $14.86B in 2024 as these precision treatments move to early-stage care.
    |Article